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Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for
the treatment of infusion pain. A randomized, double-blind, cross-over
study was undertaken to determine the effects of novel bicarbonate (38
mM) and bicarbonate (25 mM)/lactate (15 mM) containing peritoneal
dialysis (PD) solutions on infusion pain in patients who experienced inflow
pain with conventional lactate (40 mM) solution. Pain was assessed using
a verbal rating scale and the validated McGill Pain Questionnaire (MPQ).
Eighteen patients were recruited to the study. Both novel solutions
resulted in highly statistically significant reductions in inflow pain com-
pared to the control lactate solution, as assessed with both the verbal
rating scale and the MPQ. For all pain variables assessed, the bicarbonate/
lactate solution was more effective than the bicarbonate solution in
alleviating pain. In conclusion, both solutions reduced the infusion pain
experienced with control solution, but the bicarbonate/lactate solution
appears to be the most effective. In contrast to the most widespread
current treatment, which is the manual injection of sodium bicarbonate,
the bicarbonate/lactate solution does not have the associated increased
risk of peritonitis.
Abdominal pain is a common complication of peritoneal dial-
ysis (PD), with a multifactorial etiology [1–3]. For example, it has
been reported that abdominal pain occurs in 78% of patients
during an episode of peritonitis [4]. However, pain experienced
during intraperitoneal infusion of the dialysis solution also occurs
in the non-peritonitis state, and is distinguished by the abdominal
pain appearing within the first minute or so after starting infusion
of the PD solution, but which generally diminishes during the
dwell [5]. Infusion pain is usually observed in new patients
commencing dialysis and is often transient in nature, spontane-
ously disappearing over time [3, 6]. However, it is established that
infusion pain can remain a troublesome complication in PD
patients and in the most extreme cases can result in the discon-
tinuation of PD [7].
Infusion pain is generally believed to be due to the acidity (pH
5.2 to 5.5) of conventional lactate buffered dialysis solutions. Such
solutions not only contain high concentrations of lactate, but also
glucose and are acidic to minimize caramelization as well as the
chemical transformation of glucose to 5-hydroxymethylfurfural
and its acidic metabolites [7, 8]. Other factors that may contribute
to infusion pain include the position of the catheter, the temper-
ature of the dialysis solution [2], and the presence of high glucose
concentrations in the PD fluid, as it is not uncommon for patients
to predominantly experience pain during the infusion of hyper-
tonic solutions [7].
A number of actions can be employed to alleviate infusion pain.
By far the most common treatment is the neutralization of the PD
solution by the manual injection of sodium bicarbonate into the
solution immediately prior to infusion. Sodium bicarbonate is
preferred to other bases, such as hydroxide, or sodium carbonate
because of its safety, buffering action and gradual titration curve
[9]. A number of reports have demonstrated the effectiveness of
such manual injection in alleviating infusion pain [8, 10, 11].
However, the need to inject into every bag prior to infusion adds
to the therapy burden for the patient and also increases the
overall treatment cost. The greatest concern, however, is related
to the possibility that peritonitis rates are greatly increased in
patients who manually inject sodium bicarbonate due to external
contamination of the solution. For example, in a study by Hen-
derson, Couper and Lumsden [7], the peritonitis rate in 10
patients injecting bicarbonate for the treatment of inflow pain was
1 episode/4 patient months. Following cessation of bicarbonate
treatment, the peritonitis rate decreased to 1 episode/9 patient
months. Other possible actions that may be employed to treat
inflow pain include slowing the infusion rate, incomplete drainage
(including the use of tidal therapy in automated peritoneal
dialysis), manual injection of local anesthetics into the solution
prior to infusion, catheter replacement, and in the most extreme
cases transfer to hemodialysis [2].
The ideal PD solution would have a neutral pH to prevent the
occurrence of infusion pain and the need to manually inject
sodium bicarbonate. In the present study, two new solutions with
a physiological pH were evaluated. Both solutions have a pH 7.0
to 7.4, and in one solution the lactate buffer of conventional
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solutions has been replaced with a 38 mM bicarbonate buffer, and
in the other solution a combined 25 mM bicarbonate/15 mM lactate
buffer is utilized. The new solutions are presented in a two
chambered bag configuration to separate calcium and magnesium
from bicarbonate to avoid precipitation. The contents of the two
chambers are mixed prior to administration. The aim of the
present study was to assess the effectiveness of these two new
solutions in alleviating inflow pain in patients who experienced
such pain using conventional lactate containing PD solution using
a randomized, double-blind, cross-over design.
METHODS
Participating centers
The study had a prospective, randomized, double-blind, cross-
over design, where test and control solutions were studied during
single dwells. A total of 18 patients were recruited from 8
participating centers (N is the number of patients recruited at
each center): Stobhill Hospital, Glasgow, United Kingdom (N 5
4); Manchester Royal Infirmary, United Kingdom (N 5 5);
Addenbrooke’s Hospital, Cambridge, United Kingdom (N 5 3);
Royal Berkshire Hospital, Reading, United Kingdom (N 5 1);
Lasarettet, Ha¨ssleholm, Sweden (N 5 2); Ma¨larsjukhuset, Eskil-
stuna, Sweden (N 5 1); La¨nssjukhuset, Ga¨vle, Sweden (N 5 1);
Universitetssjukhuset, Linko¨ping, Sweden (N 5 1). The study
protocol was approved by the Ethics Committee of each partici-
pating center.
Study population
Patients were recruited to the study if they were at least 18 years
old, gave fully informed consent to participate, and experienced
repeated infusion pain that based on medical judgement was not
related to the catheter or excessive intraperitoneal volume of
dialysis fluid. Patients could not participate in the study if they had
been treated for peritonitis within the previous 30 days.
Eighteen patients were recruited to the study. One patient
withdrew due to transplantation during the study and was ex-
cluded from the statistical analysis. The mean age of patients at
entry was 53.5 years, with a mean time on PD of 1.7 years and the
mean length of time since first experiencing inflow pain was 16.4
months. Eleven of the 18 patients regularly used hypertonic
glucose solution of at least 3.86%, and two patients commented
that the infusion pain that they experienced was associated with
the use of the 3.86% glucose solution (see below). There was a
large variation within the eight participating centers in the fre-
quency with which infusion pain was observed within each center’s
total CAPD population. The mean frequency across all centers
was 1 in 25 (range 1 in 3 to 66) patients.
Half of the patients had experienced at least one episode of
peritonitis in the previous six months. Two-thirds of the patients
regularly injected alkalizing agents into their PD bags prior to
infusion. The 12 patients who regularly injected alkalizing agents
had a much higher incidence of peritonitis (1 episode/6 patient
months), when compared with the 6 patients who did not regularly
inject (1 episode/18 patient months). However, due to the small
sample size this difference failed to reach statistical significance
(P 5 0.131, unpaired t-test).
Study procedures and test solutions
Patients attended the participating hospital dialysis clinic for all
study exchanges. Within a one to three week period, patients were
evaluated during two dialysis exchanges with each test solution in
random order. Thus, all patients were to undergo six separate
study dwells; patients could undertake a maximum of two test
evaluations in one day, but it was required that these study
exchanges were separated by a routine dwell (40 mM lactate
solution) of at least four hours. All dwells were required to be of
at least three hours and all evaluations were undertaken using a
3.86% glucose solution, as a previous study has suggested that
infusion pain occurs more frequently with the use of hypertonic
glucose solutions [7]. The composition of the three solutions is
given in Table 1.
Due to the subjective nature of the pain response, a blinded
procedure and a validated pain questionnaire were utilized. The
identity of the solution under evaluation was unknown to the
patient as well as the study nurse. The randomized schedule for
solution administration for each patient was only known by an
attending nurse who prepared and blinded the test bag prior to
infusion (by the use of an opaque overpouch). No alkalizing
agents (that is, manual injection of sodium bicarbonate) were
permitted to be added prior to the infusion of any of the three
solutions under investigation.
Pain assessment
Pain was assessed by two methods. A five point verbal scale
(0 5 no pain, 1 5 mild pain, 2 5 moderate pain, 3 5 severe pain,
4 5 very severe pain) was administered to assess pain intensity at
the following time points: start of infusion, 1, 3, and five minutes
after start of infusion, end of infusion, 10, 30 minutes and end of
dwell, and start, five minutes and end of drain. Peak pain during
the period of infusion, dwell and drain was defined as the most
intense pain recorded with the five point verbal scale during each
period.
In addition, the validated McGill Pain Questionnaire (MPQ)
[12, 13] was completed by the patient after 40 minutes of the
dwell. The MPQ was selected as the most suitable instrument for
the assessment of inflow pain following a systematic search and
review procedure, which identified 27 questionnaires that could
potentially be suitable for use in the present study. The MPQ was
selected because of its demonstrated validity, reliability and
sensitivity, and the fact that it had previously successfully been
used in a dialysis population [14]. The MPQ aims to capture not
only the unidimensional aspects of pain related to the severity of
Table 1. The composition of the test peritoneal dialysis solutions
Solution Lactatea Bicarbonate Bicarbonate/lactate
Sodium mM 132 132 132
Calcium mM 1.25 1.25 1.25
Magnesium mM 0.25 0.25 0.25
Chloride mM 95 97 95
Bicarbonate 0 38 25
Lactate 40 0 15
Dextrose anhydrous % 3.86 3.86 3.86
pH 5.5 7.0–7.4 7.0–7.4
pCO2 mm Hg 4 77 48
Osmolality mOsm/liter 483 483 483
a Dianealt PD4 (Baxter Healthcare Corporation).
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the experience alone, as it now well established that pain is
multidimensional and the severity or intensity of the sensory
response is only one component. Thus, pain also has affective and
evaluative dimensions which disrupt ongoing behavior and
thought. Consequently, Melzack and Casey have postulated that
there are three major dimensions of pain, namely the sensory-
discriminative, motivational-affective, and cognitive-evaluative
dimensions of pain [15]. All of these dimensions of pain are
evaluated using the validated MPQ. Previous types of pain
studies undertaken using the MPQ have shown that different
types of pain (that is, headache, labor pain) have a unique
profile in terms of their effects on the different MPQ dimen-
sions and this has been used to discriminate between different
types of pain [15].
Safety was followed throughout the study by monitoring for
adverse events.
Statistical analysis
Patients were included in the statistical analysis only if they
completed the study (that is they received all of the six study
exchanges). Including patients in the analysis who dropped out
from the study could introduce a potential source of bias, as all
patients would not receive the same number of study exchanges
with each test solution. An initial analysis of variance (ANOVA)
was undertaken with terms for patients, periods (the relative
position of the six dwells), treatment and carryover [16]. If the
carryover effect was significant at the P 5 0.20 level, then an
analysis was to be used to estimate and test the differences
between the treatments. An analysis of variance (ANOVA) was
used as it was considered the most appropriate methodology
because it enabled estimates of treatment differences between the
three test solutions to be made after allowing for all other factors
in the design of the study. These other factors were: (1) differ-
ences between patients and participating centers; (2) differences
between treatment periods (that is, the order of administration of
the test solutions); and (3) any potential carryover effect by which
the treatment given at one exchange might influence the results of
subsequent evaluations. If no account were taken of these factors,
for example, if a paired or unpaired t-test had been utilized, the
results could be potentially misleading as the analysis would take
Fig. 1. Time course of pain severity time
profile in one patient during evaluation of the
control lactate solution.
Fig. 2. Frequency of peak infusion pain
severity using the verbal rating scale for the
bicarbonate (u), bicarbonate/lactate (m) and
lactate ( ) solution. The 17 patients were
evaluated with each solution on two separate
occasions.
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no account of the factors above, which could potentially bias the
results observed.
The actual study design was unbalanced due to one patient
dropping out from the study and, therefore, the three solutions
were not evaluated with equal frequency at each of the six single
dwell positions. The results presented are the actual mean for
each treatment adjusted after allowing for any possible differ-
ences as a result of the unbalanced administration. The adjusted
mean was not significantly different from the actual mean for all
variables assessed. Each patient was evaluated with each solution
on two separate occasions and, therefore, the number of obser-
vations are exactly twice the number of patients analyzed. A P
value less than 0.05 was considered statistically significant.
RESULTS
The pain severity time profile as assessed using the five-point
verbal rating scale was typical of inflow pain (Fig. 1), with the most
severe pain being observed during the first few minutes of infusion
and then reducing in severity during the course of the dwell, and
no pain being experienced during the later part of the dwell and
drain.
The majority of patients experienced inflow pain with the
control solution as assessed using the verbal rating scale (Fig. 2).
The 17 evaluable patients were evaluated during two dialysis
exchanges with each test solution in random order. All 17
evaluable patients met the entry criteria of experiencing repeated
pain on infusion, but the pain response recorded with the control
solution during the study showed a degree of variability in that no
pain was recorded on 6 of 34 (18%) test evaluations upon infusion
of the control lactate solution. Further, each patient was evalu-
ated during two dialysis exchanges with the control solution in a
random double-blind manner, and it is interesting to note that two
patients experienced no pain during both exchanges, while a
further two patients experienced no pain on only one of the
exchanges with the control solution.
Both the bicarbonate (P 5 0.001) and the bicarbonate/lactate
(P 5 0.001) solutions produced lower recorded peak pain during
infusion compared to the lactate solution as assessed using the
five-point verbal rating scale (Fig. 3).
Pain of reduced intensity was also recorded in some patients
during the dwell and drain periods (Fig. 3), despite the fact that all
patients at entry met the inclusion criteria of experiencing re-
peated pain on infusion. Differences in the degree of pain
reduction between the two bicarbonate containing solutions were
also observed. The adjusted mean pain score for bicarbonate/
lactate was lower than the corresponding score for the bicarbon-
ate solution for peak pain during infusion, dwell and drain. This
Fig. 3. Peak pain verbal rating scale response (0 5 no pain, 1 5 mild
pain, 2 5 moderate pain, 3 5 severe pain, 4 5 very severe pain) for the
lactate, bicarbonate and bicarbonate/lactate solution during (A) infusion,
(B) dwell and (C) drain. Each condition represents the adjusted mean 6
SEM for 34 separate evaluations of each solution. P values were calculated
by ANOVA.
Fig. 4. Effects of the lactate, bicarbonate and the bicarbonate/lactate
solutions on the (A) total weighted pain rating index, (B) number of words
chosen and (C) present pain intensity of the McGill Pain Questionnaire.
Each condition represents the adjusted mean 6 SEM for 34 separate
evaluations of each solution. P values were calculated by ANOVA.
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difference was statistically significant for peak pain during dwell
(P 5 0.048) and drain (P 5 0.011).
Similar results for the effects of the study solutions on inflow
pain were obtained with the MPQ (Figs. 4 and 5). Both the
bicarbonate (P 5 0.0002) and bicarbonate/lactate (P 5 0.0001)
solutions produced statistically significant lower scores for the
total weighted pain rating index for the MPQ when compared to
the control lactate solution. Furthermore, the total weighted pain
rating index was lower for bicarbonate/lactate compared to the
bicarbonate solution. Similar results were obtained for the indi-
vidual MPQ dimensions (affective, evaluative, sensory, miscella-
neous), the number of words chosen (which assesses pain severity)
and the present pain intensity.
Following completion of each test evaluation, patients were
asked to respond yes or no to the three questions shown in
Table 2. Patient responses to all questions suggested that the
intensity of the pain response was diminished with both the
bicarbonate and bicarbonate/lactate solution compared to the
control lactate solution. Furthermore, the patient responses to
two of the three questions indicated that less severe pain was
experienced with bicarbonate/lactate compared to the bicar-
bonate solution.
Two adverse events that were classified by the investigator as
having a probable or possible relationship to the study solutions
were recorded during the study. Both adverse events (general
pruritus of mild severity and severe sweating) resulted from the
administration of the control lactate solution.
DISCUSSION
Due to the subjective nature of the pain response, it was
important in the present study to minimize any bias due to the
patient or study nurse being aware of the identity of the solution
being evaluated. This was overcome by the randomized, double-
blind, cross-over design employed, and the fact that each patient
was evaluated with each solution on two occasions. Furthermore,
it is well established that infusion pain tends to diminish with
time on PD [3, 6]. The present study ensured that patients were
studied in as short a time as reasonably possible and, by using
a randomized design, no differences in effectiveness could be
attributed to a reduction in pain intensity with time. Further-
more, a percentage of patients experienced no infusion pain
Fig. 5. Effects of the lactate, bicarbonate and the bicarbonate/lactate solutions on individual dimensions of the McGill Pain Questionnaire: (A)
affective dimension; (B) sensory dimension; (C) evaluative dimension; (D) miscellaneous dimension. Each condition represents the adjusted mean 6
SEM for 34 separate evaluations of each solution. P values were calculated by ANOVA.
Table 2. Inflow pain related questions %
Question
Lactate Bicarbonate Bicarbonate/lactate
Yes No Yes No Yes No
“Did you feel the fluid
going in on infusion?”
58.8 41.2 26.2 73.5 23.5 76.5
“Would you describe
infusion as painful?”
52.9 47.1 5.9 94.1 8.8 91.2
“Did pain appear
instantly, at the first
second of infusion?”
20.6 79.4 8.8 91.2 0.0 100
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when evaluated with the control lactate solution. Previous
studies of new potential treatments for infusion pain have
unfortunately not utilized such a vigorous design and, there-
fore, their conclusions should be interpreted with some caution
[8, 10, 11, 17]. Furthermore, it is recommended that all future
studies assessing the effectiveness of new treatments for infu-
sion pain utilize a similar vigorous design to that used in this
study.
In the present study, both the bicarbonate and bicarbonate/
lactate solution resulted in a significant reduction in infusion pain
in patients who experienced such pain with conventional lactate
buffered solution. These effects were demonstrated using both a
pain severity rating index and the validated MPQ. There was a
degree of variability in the pain response observed upon infusion
of the control lactate solution, with the mean pain severity being
intermediate between mild and moderate. This variability was
observed between and within patients. The adjusted mean pain
score for the total weighted pain rating index of the MPQ was
similar to the recorded pain for the symptoms of cramps and bone
pain previously studied in hemodialysis patients [14]. The pain
severity experienced in the present study is likely to be an
underestimate of the actual pain severity experienced in this
patient population, as two of the patients were permitted for
compassionate reasons (although a violation of the study proto-
col) to inject alkalizing agents to relieve intolerable pain
following the infusion of the control lactate solution. It should
be pointed out that due to the double-blind nature of the study
both patients were unaware that the control solution was being
evaluated. Pain, albeit of reduced severity, was also observed
during the dwell and drain periods with the control solution,
but only the bicarbonate/lactate solution produced a reduction
in the pain intensity compared to both the control lactate and
bicarbonate solution.
For all pain variables assessed with both the verbal rating scale
and the MPQ, lower pain scores were seen with the bicarbonate/
lactate compared to the bicarbonate solution, and for two of the
variables assessed (peak pain during dwell and drain), this differ-
ence was statistically significant. This difference was supported by
the patient responses to the additional questions asked at the end
of each test evaluation. In addition, the bicarbonate solution
appeared to result in more intense pain than the control lactate
solution during the dwell and drain periods. The fact that
bicarbonate/lactate would appear to be more effective than the
bicarbonate solution in reducing inflow pain raises the possibility
that such pain is not entirely due to pH as both solutions have
identical pH. One possible explanation could be due to differ-
ences in the pCO2 of the two bicarbonate containing solutions.
Indeed, pCO2 in the solutions was measured at 37°C by injecting
a sample of freshly mixed solution into a blood gas analyzer,
equipped with a pCO2 electrode and the pure bicarbonate
solution had a significantly higher value than the combined
solution (Table 1). It is more difficult to explain why the bicar-
bonate solution would apparently result in more intense pain
during dwell and drain than the conventional lactate solution.
One explanation could be the high pCO2 level or the relatively
high concentration (38 mM) of bicarbonate compared to a normal
plasma level of approximately 25 mM [18]. Indeed, some aspects of
cellular function are better preserved in vitro with bicarbonate/
lactate than a pure bicarbonate solution [19–22].
In agreement with a previous report [7], the present study
demonstrated that peritonitis rates are higher in patients who
manually inject alkalizing agents prior to infusion to alleviate
pain. Although patients were only exposed to the novel solutions
for a relatively short time interval, no episodes of peritonitis were
observed following use of the bicarbonate solutions in the present
study, and a previous two month evaluation in 47 patients has
demonstrated that the bicarbonate containing solutions have
similar peritonitis rates to conventional lactate containing solu-
tions [18].
In conclusion, both the bicarbonate and bicarbonate/lactate
solution were effective in reducing the intensity of pain associated
with the infusion of conventional lactate based PD solutions. The
bicarbonate/lactate solution would appear to be more effective in
alleviating inflow pain than the bicarbonate solution. This ob-
served difference supports the hypothesis that the cause of inflow
pain may be multifactorial and not just related to pH. Further-
more, the use of the bicarbonate/lactate solution for the treatment
of inflow pain has the advantages over the most widespread
current treatment, namely the manual injection of alkalizing
agents, of not adding to the therapy burden of the patient and,
most importantly, not increasing the risk of peritonitis.
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